Cargando…

Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics

BACKGROUND: Sublingual allergen‐specific immunotherapy (SLIT) intervention improves the control of grass pollen allergy by maintaining allergen tolerance after cessation. Despite its widespread use, little is known about systemic effects and kinetics associated to SLIT, as well as the influence of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Barker‐Tejeda, Tomas Clive, Bazire, Raphaelle, Obeso, David, Mera‐Berriatua, Leticia, Rosace, Domenico, Vazquez‐Cortes, Sonia, Ramos, Tania, Rico, Maria del Pilar, Chivato, Tomás, Barbas, Coral, Villaseñor, Alma, Escribese, Maria M., Fernández‐Rivas, Montserrat, Blanco, Carlos, Barber, Domingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246889/
https://www.ncbi.nlm.nih.gov/pubmed/32813887
http://dx.doi.org/10.1111/all.14565
_version_ 1783716405526396928
author Barker‐Tejeda, Tomas Clive
Bazire, Raphaelle
Obeso, David
Mera‐Berriatua, Leticia
Rosace, Domenico
Vazquez‐Cortes, Sonia
Ramos, Tania
Rico, Maria del Pilar
Chivato, Tomás
Barbas, Coral
Villaseñor, Alma
Escribese, Maria M.
Fernández‐Rivas, Montserrat
Blanco, Carlos
Barber, Domingo
author_facet Barker‐Tejeda, Tomas Clive
Bazire, Raphaelle
Obeso, David
Mera‐Berriatua, Leticia
Rosace, Domenico
Vazquez‐Cortes, Sonia
Ramos, Tania
Rico, Maria del Pilar
Chivato, Tomás
Barbas, Coral
Villaseñor, Alma
Escribese, Maria M.
Fernández‐Rivas, Montserrat
Blanco, Carlos
Barber, Domingo
author_sort Barker‐Tejeda, Tomas Clive
collection PubMed
description BACKGROUND: Sublingual allergen‐specific immunotherapy (SLIT) intervention improves the control of grass pollen allergy by maintaining allergen tolerance after cessation. Despite its widespread use, little is known about systemic effects and kinetics associated to SLIT, as well as the influence of the patient sensitization phenotype (Mono‐ or Poly‐sensitized). In this quest, omics sciences could help to gain new insights to understand SLIT effects. METHODS: 47 grass‐pollen‐allergic patients were enrolled in a double‐blind, placebo‐controlled, multicenter trial using GRAZAX® during 2 years. Immunological assays (sIgE, sIgG4, and ISAC) were carried out to 31 patients who finished the trial. Additionally, serum and PBMCs samples were analyzed by metabolomics and transcriptomics, respectively. Based on their sensitization level, 22 patients were allocated in Mono‐ or Poly‐sensitized groups, excluding patients allergic to epithelia. Individuals were compared based on their treatment (Active/Placebo) and sensitization level (Mono/Poly). RESULTS: Kinetics of serological changes agreed with those previously described. At two years of SLIT, there are scarce systemic changes that could be associated to improvement in systemic inflammation. Poly‐sensitized patients presented a higher inflammation at inclusion, while Mono‐sensitized patients presented a reduced activity of mast cells and phagocytes as an effect of the treatment. CONCLUSIONS: The most relevant systemic change detected after two years of SLIT was the desensitization of effector cells, which was only detected in Mono‐sensitized patients. This change may be related to the clinical improvement, as previously reported, and, together with the other results, may explain why clinical effect is lost if SLIT is discontinued at this point.
format Online
Article
Text
id pubmed-8246889
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82468892021-07-02 Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics Barker‐Tejeda, Tomas Clive Bazire, Raphaelle Obeso, David Mera‐Berriatua, Leticia Rosace, Domenico Vazquez‐Cortes, Sonia Ramos, Tania Rico, Maria del Pilar Chivato, Tomás Barbas, Coral Villaseñor, Alma Escribese, Maria M. Fernández‐Rivas, Montserrat Blanco, Carlos Barber, Domingo Allergy ORIGINAL ARTICLES BACKGROUND: Sublingual allergen‐specific immunotherapy (SLIT) intervention improves the control of grass pollen allergy by maintaining allergen tolerance after cessation. Despite its widespread use, little is known about systemic effects and kinetics associated to SLIT, as well as the influence of the patient sensitization phenotype (Mono‐ or Poly‐sensitized). In this quest, omics sciences could help to gain new insights to understand SLIT effects. METHODS: 47 grass‐pollen‐allergic patients were enrolled in a double‐blind, placebo‐controlled, multicenter trial using GRAZAX® during 2 years. Immunological assays (sIgE, sIgG4, and ISAC) were carried out to 31 patients who finished the trial. Additionally, serum and PBMCs samples were analyzed by metabolomics and transcriptomics, respectively. Based on their sensitization level, 22 patients were allocated in Mono‐ or Poly‐sensitized groups, excluding patients allergic to epithelia. Individuals were compared based on their treatment (Active/Placebo) and sensitization level (Mono/Poly). RESULTS: Kinetics of serological changes agreed with those previously described. At two years of SLIT, there are scarce systemic changes that could be associated to improvement in systemic inflammation. Poly‐sensitized patients presented a higher inflammation at inclusion, while Mono‐sensitized patients presented a reduced activity of mast cells and phagocytes as an effect of the treatment. CONCLUSIONS: The most relevant systemic change detected after two years of SLIT was the desensitization of effector cells, which was only detected in Mono‐sensitized patients. This change may be related to the clinical improvement, as previously reported, and, together with the other results, may explain why clinical effect is lost if SLIT is discontinued at this point. John Wiley and Sons Inc. 2020-09-22 2021-04 /pmc/articles/PMC8246889/ /pubmed/32813887 http://dx.doi.org/10.1111/all.14565 Text en © 2020 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle ORIGINAL ARTICLES
Barker‐Tejeda, Tomas Clive
Bazire, Raphaelle
Obeso, David
Mera‐Berriatua, Leticia
Rosace, Domenico
Vazquez‐Cortes, Sonia
Ramos, Tania
Rico, Maria del Pilar
Chivato, Tomás
Barbas, Coral
Villaseñor, Alma
Escribese, Maria M.
Fernández‐Rivas, Montserrat
Blanco, Carlos
Barber, Domingo
Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics
title Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics
title_full Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics
title_fullStr Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics
title_full_unstemmed Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics
title_short Exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics
title_sort exploring novel systemic biomarker approaches in grass‐pollen sublingual immunotherapy using omics
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246889/
https://www.ncbi.nlm.nih.gov/pubmed/32813887
http://dx.doi.org/10.1111/all.14565
work_keys_str_mv AT barkertejedatomasclive exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics
AT bazireraphaelle exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics
AT obesodavid exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics
AT meraberriatualeticia exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics
AT rosacedomenico exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics
AT vazquezcortessonia exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics
AT ramostania exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics
AT ricomariadelpilar exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics
AT chivatotomas exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics
AT barbascoral exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics
AT villasenoralma exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics
AT escribesemariam exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics
AT fernandezrivasmontserrat exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics
AT blancocarlos exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics
AT barberdomingo exploringnovelsystemicbiomarkerapproachesingrasspollensublingualimmunotherapyusingomics